Guidant’s Drug-Eluting Stent Program Reboots With 140-Patient Dose Trial
This article was originally published in The Gray Sheet
Executive Summary
The need to perform dosing studies before attempting a large-scale clinical trial of a drug-eluting coronary stent is demonstrated by early results of Guidant's DELIVER trial, Angiotech maintains
You may also be interested in...
Dissecting DELIVER: Dosing, Non-Polymer Binding Implicated In Guidant Trial
The role of insufficient dosing in the DELIVER trial evaluating Guidant's Achieve drug-eluting stent will likely emerge in presentations at the American College of Cardiology's annual meeting in Chicago March 30-April 2
Dissecting DELIVER: Dosing, Non-Polymer Binding Implicated In Guidant Trial
The role of insufficient dosing in the DELIVER trial evaluating Guidant's Achieve drug-eluting stent will likely emerge in presentations at the American College of Cardiology's annual meeting in Chicago March 30-April 2
Guidant Shifts To Everolimus As Stents Developed With Cook Under-Achieve
Guidant will pursue development of two polymer-coated everolimus-eluting stent platforms in the wake of disappointing study results with its Achieve non-polymer paclitaxel-eluting stent